Literature DB >> 2824913

Opioid receptors and endogenous opioids in diverse human and animal cancers.

I S Zagon1, P J McLaughlin, S R Goodman, R E Rhodes.   

Abstract

Receptor binding studies demonstrated specific high-affinity, saturable binding of a number of opioid ligands to a wide variety of neural and nonneural human and animal tumors. Radioimmunoassays revealed the presence of beta-endorphin and methionine-enkephalin in these tumors. Both methionine- and leucine-enkephalin were detected in tumor tissue by immunocytochemistry, with immunoreactivity related to the cortical cytoplasm of tumor cells, but not to cell nuclei. Endogenous opioids and receptors were found in benign and malignant tumors representative of ectodermal, mesodermal, and endodermal origin. Receptors and endogenous opioid peptides were present in tumors from many different species, including those transplanted into nude mice. These results suggest that opioid receptors and endogenous opioids are fundamental features of human and animal cancers.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824913

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  24 in total

1.  Delta-Opioid Receptor (δOR) Targeted Near-Infrared Fluorescent Agent for Imaging of Lung Cancer: Synthesis and Evaluation In Vitro and In Vivo.

Authors:  Allison S Cohen; Renata Patek; Steven A Enkemann; Joseph O Johnson; Tingan Chen; Eric Toloza; Josef Vagner; David L Morse
Journal:  Bioconjug Chem       Date:  2015-10-30       Impact factor: 4.774

Review 2.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 3.  Opioid growth factor and the treatment of human pancreatic cancer: a review.

Authors:  Ian S Zagon; Patricia J McLaughlin
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  Immunoreactive opioid peptides in human breast cancer.

Authors:  L Scopsi; E Balslev; N Brünner; H S Poulsen; J Andersen; F Rank; L I Larsson
Journal:  Am J Pathol       Date:  1989-02       Impact factor: 4.307

5.  Exogenous OGF enhances the anti-tumor activity of cisplatin on hepatocellular carcinoma.

Authors:  Yinhe Sikong; Qing Wang; Meijuan Cai; Aijun Zhang; Fei Pang; Xiangdan Cui
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

6.  Tumor Targeting and Pharmacokinetics of a Near-Infrared Fluorescent-Labeled δ-Opioid Receptor Antagonist Agent, Dmt-Tic-Cy5.

Authors:  Amanda Shanks Huynh; Veronica Estrella; Valerie E Stark; Allison S Cohen; Tingan Chen; Todd J Casagni; Jatinder S Josan; Mark C Lloyd; Joseph Johnson; Jongphil Kim; Victor J Hruby; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2016-01-08       Impact factor: 4.939

7.  Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment.

Authors:  Moshe Rogosnitzky; Milton J Finegold; Patricia J McLaughlin; Ian S Zagon
Journal:  Invest New Drugs       Date:  2012-12-30       Impact factor: 3.850

Review 8.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

9.  Solid-phase synthetic strategy and bioevaluation of a labeled delta-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging.

Authors:  Jatinder S Josan; David L Morse; Liping Xu; Maria Trissal; Brenda Baggett; Peg Davis; Josef Vagner; Robert J Gillies; Victor J Hruby
Journal:  Org Lett       Date:  2009-06-18       Impact factor: 6.005

10.  The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer.

Authors:  Diego M Avella; Eric T Kimchi; Renee N Donahue; Hephzibah Rani S Tagaram; Patricia J McLaughlin; Ian S Zagon; Kevin F Staveley-O'Carroll
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-18       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.